Traffic:
10E
10W
15N
15S
57N
57S
60E
60W
210E
210W
This Site
Web Search
powered by
YAHOO! SEARCH
Subscriber Services
|
Home Delivery
|
e-Edition
|
Alerts
|
RSS
Home
News
Ontario
Rancho Cucamonga
Pomona
Upland
Claremont
Montclair
Chino Valley
California
Crime & Public Safety
Elections
Education
S.B. County Watch
Upland Watch
I.E.: Medicare Testing Ground
Sports
Buy Event Tickets Now
Golf - Tee Times and Courses
Preps
Reign Hockey
Rancho Cucamonga Quakes
Local Colleges
USC
UCLA
Lakers
Clippers
Dodgers
Angels
Ducks
Soccer
Motor Sports
Horse Racing
Live Odds
Business
Autos
Real Estate News
Technology
Opinions
Editorial
Letters
Columnists
Blogs
LA.COM
Buy Tickets
Movies
TV
Music
Shopping & Beauty
Recreation
Neighborhood
Arts
Living
Dining
Find A Restaurant
Lottery
Horoscopes
Travel
Trevor's Travels
Health
Crossword Puzzle
Local Casinos
Foothills Magazine
Info
Subscribe For Home Delivery
Contact Us
RSS
Podcast
Subscriber Services
Place An Ad
NIE
Classified
Place an Ad
Homes
Jobs
Auto
Search autos
Buy/Sell a car
Research/Financing a car
Find a dealer
Shopping
This week's ads
Obits
Directories
Local Business
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Neogenomics Inc
(NQ:
NEO
)
16.29
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Neogenomics Inc
< Previous
1
2
3
4
5
6
Next >
NeoGenomics to Present New Data at ESMO 2024, Highlighting the Value of ctDNA and NGS for Advancing Cancer Diagnostics and Personalized Treatment
September 11, 2024
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
August 29, 2024
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics Reports Second Quarter 2024 Results
July 29, 2024
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics Reports Third Quarter 2023 Results
November 06, 2023
Via
ACCESSWIRE
NeoGenomics Reports Second Quarter 2023 Results
August 08, 2023
Via
ACCESSWIRE
NeoGenomics to Report Second Quarter 2024 Financial Results on July 29, 2024
July 09, 2024
From
NeoGenomics, Inc.
Via
Business Wire
Fort Myers’ Mayor to Proclaim June as NeoGenomics’ Commitment to Cancer Month
June 13, 2024
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics to Introduce Comprehensive Lung Solution & Feature Hematopathology Services at ASCO, Offering Actionable Insights to Support Treatment Management
May 28, 2024
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics Reports First Quarter 2024 Results
April 30, 2024
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics Announces Senior Leadership Promotions
April 18, 2024
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics to Report First Quarter 2024 Financial Results on April 30, 2024
April 09, 2024
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics Showcases Commitment to Transforming Cancer Patient Care at AACR 2024 Annual Meeting
March 27, 2024
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics Releases Inaugural Environmental, Social, and Governance (ESG) Report
March 20, 2024
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics to Participate in the TD Cowen 44th Annual Health Care Conference
March 01, 2024
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics Reports Fourth Quarter and Full Year 2023 Results
February 20, 2024
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics Signs Working with Cancer Pledge in Support of Employees
February 01, 2024
From
NeoGenomics, Inc.
Via
Business Wire
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
January 30, 2024
EQNX::TICKER_START (OTCQB:TDSGF),(TSXV:TELO),(NYSE:BMY),(NYSE:TMO),(NASDAQ:NTRA),(NASDAQ:NEO) EQNX::TICKER_END
Via
FinancialNewsMedia
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
January 30, 2024
From
FN Media Group LLC
Via
GlobeNewswire
NeoGenomics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20, 2024
January 30, 2024
From
NeoGenomics, Inc.
Via
Business Wire
ROSEN, A LEADING NATIONAL FIRM, Encourages NeoGenomics, Inc. Investors to Inquire About Securities Class Action Investigation – NEO
January 02, 2024
From
The Rosen Law Firm, P.A.
Via
Business Wire
NeoGenomics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics to Appeal Ruling
December 28, 2023
Via
ACCESSWIRE
NeoGenomics to Present New Data at San Antonio Breast Cancer Symposium Highlighting Utility of RaDaR for Therapy Response
December 05, 2023
Via
ACCESSWIRE
NeoGenomics to Participate at the Piper Sandler 35th Annual Healthcare Conference
November 14, 2023
Via
ACCESSWIRE
NeoGenomics Announces the Commercial Availability of Two New Tests, Expanding Its Next-Generation Sequencing and Lung Cancer Portfolios
October 24, 2023
Via
ACCESSWIRE
NeoGenomics to Report Third Quarter 2023 Financial Results on November 6, 2023
October 17, 2023
Via
ACCESSWIRE
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
October 17, 2023
EQNX::TICKER_START (OTCQB:TDSGF),(TSXV:TELO),(NASDAQ:GH),(NASDAQ:NTRA),(NYSE:DGX),(NASDAQ:NEO) EQNX::TICKER_END
Via
FinancialNewsMedia
NeoGenomics Announces Medicare Coverage for RaDaR Assay for Minimal Residual Disease and Recurrence in Breast Cancer
July 27, 2023
Via
ACCESSWIRE
NeoGenomics to Report Second Quarter 2023 Financial Results on August 8, 2023
July 18, 2023
Via
ACCESSWIRE
NeoGenomics Expands Board of Directors with Appointments of Three Independent Directors
June 29, 2023
Via
ACCESSWIRE
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Privacy Policy
|
Terms of Use
|
MNG Corporate Site Map
|
Copyright